From the Department of Hematopathology, The University of Texas MD Anderson Cancer Center; Universidad Peruana de Ciencias Aplicadas; Department of Hematopathology, The University of Texas MD Anderson Cancer Center; MultiCare Regional Cancer Center, MultiCare Health Systems; Department of Plastic Surgery, Keck School of Medicine, University of Southern California; Department of Pathology, VU University Medical Center; Department of Pathology, Memorial Sloan Kettering Cancer Center; and Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center.
Plast Reconstr Surg. 2019 Mar;143(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma):7S-14S. doi: 10.1097/PRS.0000000000005564.
The first case of breast implant-associated anaplastic large cell lymphoma (breast implant ALCL) was described by John Keech and the late Brevator Creech in 1997. In the following 2 decades, much research has led to acceptance of breast implant ALCL as a specific clinicopathologic entity, a process that we bring up to life through the memories of 6 persons who were involved in this progress, although we acknowledge that many others also have contributed to the current state of the art of this disease. Dr. Keech recalls the events that led him and Creech to first report the disease. Ahmet Dogan and colleagues at the Mayo Clinic described a series of 4 patients with breast implant ALCL, and led to increased awareness of breast implant ALCL in the pathology community. Daphne de Jong and colleagues in the Netherlands were the first to provide epidemiologic evidence to support the association between breast implants and ALCL. Garry Brody was one of the first investigators to collect a large number of patients with the disease, present the spectrum of clinical findings, and alert the community of plastic surgeons. Roberto Miranda and L. Jeffrey Medeiros and colleagues studied the pathologic findings of a large number of cases of breast implant ALCL, and published the findings in 2 impactful studies in the medical oncology literature. The recognition and acceptance of this disease by surgeons, epidemiologists, and medical oncologists, working together, has led to subsequent studies on the pathogenesis and optimal therapy of this disease.
首例乳房植入物相关间变性大细胞淋巴瘤(乳房植入物 ALCL)是由 John Keech 和已故的 Brevator Creech 于 1997 年描述的。在接下来的 20 年中,大量研究使乳房植入物 ALCL 被接受为一种特定的临床病理实体,我们通过参与这一进展的 6 个人的回忆来展示这一过程,尽管我们承认许多其他人也为该疾病的当前现状做出了贡献。Keech 博士回忆了促使他和 Creech 首次报告该疾病的事件。Mayo 诊所的 Ahmet Dogan 及其同事描述了一系列 4 例乳房植入物 ALCL 患者,并导致病理学界对乳房植入物 ALCL 的认识提高。荷兰的 Daphne de Jong 及其同事首次提供了流行病学证据,支持乳房植入物与 ALCL 之间的关联。Garry Brody 是最早收集大量该疾病患者的研究人员之一,提出了一系列临床表现,并提醒整形外科医生注意该疾病。Roberto Miranda 和 L. Jeffrey Medeiros 及其同事研究了大量乳房植入物 ALCL 病例的病理发现,并在医学肿瘤学文献中发表了两项有影响力的研究结果。外科医生、流行病学家和肿瘤内科医生共同认识和接受这种疾病,随后进行了关于这种疾病发病机制和最佳治疗方法的研究。